

Comprehensive GBM Study Analysis

Generated on: September 24, 2025 at 12:22 AM

Executive Summary

Metric	Value
Total Patients	43
Patients with Survival Data	38
Mean Overall Survival (days)	723.2
Progression Rate	55.8%
Overall Response Rate	0.0%

Survival Analysis

Survival Metric	Mean (days)	Median (days)	Sample Size
Overall Survival	723.2	702.5	38
Time to Progression	566.2	543.5	24
Progression-Free Survival	625.3	602.0	38

Key Findings:

- 43 of 43 patients are alive
- 24 patients have experienced progression
- Progression rate: 55.8%

Treatment Response Analysis


No treatment response data available.

Molecular Marker Correlations

Biomarker	Category	Count	Percentage
IDH Status	Wildtype	33	78.6%
IDH Status	Unknown	3	7.1%
IDH Status	Mutant	6	14.3%

MGMT Status	Unmethylated	20	47.6%
MGMT Status	Methylated	19	45.2%
MGMT Status	Unknown	3	7.1%

Statistical Visualizations



Methodology and Notes

Data Analysis Methodology:

- Survival metrics calculated from diagnosis date to last follow-up or event
- Time-to-progression defined as time from diagnosis to first progressive disease
- Treatment response assessed using RECIST criteria when available
- Molecular markers analyzed for correlation with clinical outcomes
- Statistical calculations performed using standard clinical research methods

Limitations:

- Analysis based on available data; missing data may affect results
- Follow-up times may vary between patients
- Treatment response assessment dependent on imaging availability

Generated by: GBM Tracker Advanced Analytics Engine

Report Date: September 24, 2025